Open AccessVALSARTAN IN PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES
Author(s) -
M. Л. Максимов,
А. С. Ермолаева,
О. В. Дралова
Publication year - 2013
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2013-19-5-458-471
Subject(s) - valsartan , medicine , diabetes mellitus , heart failure , pharmacotherapy , cardiology , antihypertensive drug , drug , metabolic syndrome , sacubitril , type 2 diabetes mellitus , pharmacology , blood pressure , endocrinology
Angiotensin receptor blockers represent a relevant group of cardiovascular drugs. The results of clinical trials of a generic Valsartan (Valsakor) are reviewed in the paper. Valsartan combines high antihypertensive and organoprotective effects with the low risk of signiicant drug interactions. Due to the favorable metabolic proile valsartan is the drug of choice in hypertension, metabolic syndrome and type 2 diabetes mellitus, and the long-term therapy is associated with the reduction of the risk of new-onset diabetes. Valsartan is effective in primary and secondary prevention of atrial ibrillation, congestive heart failure and chronic renal failure.